MedCity News December 8, 2025
Theranostics — which combines molecular imaging with targeted therapy — is quickly becoming a significant innovation in cancer care, offering more precise treatment with fewer side effects. GE Healthcare expects the field to grow rapidly over the next decade, as long as hospitals can continue to invest in the imaging and software infrastructure needed to scale these therapies.
The evolving field of theranostics is poised to broaden treatment options for millions of cancer patients, according to one GE Healthcare leader.
“Theranostics is the combination of diagnostics and therapy — but it’s much deeper than that,” said Sergio Calvo, global general manager of theranostics at GE Healthcare, during an interview at the Radiological Society of North America’s annual conference last week...
Today's Sponsors
Today's Sponsor